Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages

Maze Therapeutics, Inc. (NASDAQ:MAZE) has received an average rating of “Buy” from the eleven research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $66.00.

A number of research analysts have recently commented on MAZE shares. Guggenheim upped their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Wall Street Zen lowered shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Truist Financial dropped their price target on shares of Maze Therapeutics from $68.00 to $64.00 and set a “buy” rating for the company in a research report on Tuesday, April 14th. BTIG Research reissued a “buy” rating and issued a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, March 25th. Finally, JPMorgan Chase & Co. increased their price target on shares of Maze Therapeutics from $52.00 to $58.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 31st.

Maze Therapeutics Stock Performance

Shares of MAZE opened at $27.27 on Monday. The company has a 50-day simple moving average of $36.92 and a 200-day simple moving average of $38.18. The firm has a market capitalization of $1.36 billion, a P/E ratio of -8.44 and a beta of 2.50. Maze Therapeutics has a 52 week low of $8.24 and a 52 week high of $53.65.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. As a group, equities analysts forecast that Maze Therapeutics will post -2.59 earnings per share for the current year.

Insider Buying and Selling

In related news, CMO Harold Bernstein sold 30,000 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $50.45, for a total value of $1,513,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Atul Dandekar sold 7,500 shares of the stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $25.37, for a total transaction of $190,275.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at $266,461.11. This trade represents a 41.66% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 70,000 shares of company stock valued at $2,955,775 over the last quarter.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada raised its position in Maze Therapeutics by 128.3% in the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after purchasing an additional 363 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock worth $42,000 after purchasing an additional 738 shares in the last quarter. California State Teachers Retirement System increased its holdings in shares of Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after buying an additional 766 shares in the last quarter. Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Maze Therapeutics by 18.5% during the fourth quarter. Police & Firemen s Retirement System of New Jersey now owns 5,961 shares of the company’s stock worth $247,000 after buying an additional 931 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in shares of Maze Therapeutics during the fourth quarter worth approximately $39,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.